Clinical Trials

10 results for Bladder Cancer

A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer

  • Condition: Urothelial Carcinoma of the Urinary Bladder
  • Intervention:
  • Study ID: NCT02202772
View Trial

PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER - (ADAPT-BLADDER) HCRN GU16-243

  • Condition: Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Durvalumab, Radiation: External Beam Radiotherapy (EBRT), Biological: Bacillus Calmette-Guérin (BCG)
  • Study ID: NCT03317158
View Trial

Phase II Study of Pembrolizumab (MK-3475) as First-Line Therapy for High Risk T1 Non-Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Pembrolizumab (MK-3475)
  • Study ID: NCT03504163
View Trial

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: ALT-803, Drug: BCG
  • Study ID: NCT03022825
View Trial

An Open Label, Randomized, Phase III Trial, Evaluating Efficacy of Atezolizumab in Addition to One Year BCG (Bacillus CaLmette-Guerin) Bladder Instillation in BCG-naive Patients With High-risk Non-muscle Invasive Bladder cANcer

  • Condition: Bladder Cancer
  • Intervention: Drug: BCG, Drug: Atezolizumab
  • Study ID: NCT03799835
View Trial

Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study

  • Condition: Superficial Bladder Cancer
  • Intervention: Drug: abnobaVISCUM 900, Drug: Mitomycin C
  • Study ID: NCT02106572
View Trial

Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma

  • Condition: Bladder Cancer
  • Intervention: Drug: BCG instillation therapy, Drug: Sequential BCG and EMDA mitomycin C
  • Study ID: NCT03664869
View Trial

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

  • Condition: Bladder Urothelial Carcinoma In Situ, High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma, Infiltrating Bladder Mixed Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
  • Intervention: Drug: Gemcitabine, Drug: Gemcitabine Hydrochloride, Biological: Pembrolizumab
  • Study ID: NCT04164082
View Trial

A Phase II Clinical Study of Intravesical Photodynamic Therapy in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Or Patients Who Are Intolerant to BCG Therapy ("Study").

  • Condition: Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
  • Intervention: Combination Product: TLD-1433 Bladder infusion and Photodynamic Therapy
  • Study ID: NCT03945162
View Trial

A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions

  • Condition: Urinary Bladder Neoplasms
  • Intervention: Drug: Erdafitinib, Drug: Investigator Choice (Gemcitabine), Drug: Investigator Choice (Mitomycin C)
  • Study ID: NCT04172675
View Trial